Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Gut

Retrieve available abstracts of 104 articles:
HTML format
Text format



Single Articles


    May 2019
  1. ZUNDLER S, Becker E, Schulze LL, Neurath MF, et al
    Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances.
    Gut. 2019 May 24. pii: gutjnl-2018-317977. doi: 10.1136/gutjnl-2018-317977.
    PubMed     Text format     Abstract available


  2. LYNGE E, Petersen MS, Lophaven SN
    Inflammatory bowel disease and Parkinson's disease.
    Gut. 2019 May 10. pii: gutjnl-2019-318958. doi: 10.1136/gutjnl-2019-318958.
    PubMed     Text format    


  3. BUTWICKA A, Sariaslan A, Larsson H, Halfvarson J, et al
    No association between urbanisation, neighbourhood deprivation and IBD: a population-based study of 4 million individuals.
    Gut. 2019;68:947-948.
    PubMed     Text format    


  4. MEDDENS CA, van der List ACJ, Nieuwenhuis EES, Mokry M, et al
    Non-coding DNA in IBD: from sequence variation in DNA regulatory elements to novel therapeutic potential.
    Gut. 2019;68:928-941.
    PubMed     Text format     Abstract available


  5. SCHMITT H, Billmeier U, Dieterich W, Rath T, et al
    Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease.
    Gut. 2019;68:814-828.
    PubMed     Text format     Abstract available


    April 2019
  6. GAUJOUX R, Starosvetsky E, Maimon N, Vallania F, et al
    Cell-centred meta-analysis reveals baseline predictors of anti-TNFalpha non-response in biopsy and blood of patients with IBD.
    Gut. 2019;68:604-614.
    PubMed     Text format     Abstract available


  7. TOMINAGA K, Tsuchiya A, Yokoyama J, Terai S, et al
    How do you treat this diversion ileitis and pouchitis?
    Gut. 2019;68:593-758.
    PubMed     Text format    


  8. MAGRO F, Lopes J, Borralho P, Lopes S, et al
    Comparison of different histological indexes in the assessment of UC activity and their accuracy regarding endoscopic outcomes and faecal calprotectin levels.
    Gut. 2019;68:594-603.
    PubMed     Text format     Abstract available


    March 2019
  9. VAN DER POST S, Jabbar KS, Birchenough G, Arike L, et al
    Structural weakening of the colonic mucus barrier is an early event in ulcerative colitis pathogenesis.
    Gut. 2019 Mar 26. pii: gutjnl-2018-317571. doi: 10.1136/gutjnl-2018-317571.
    PubMed     Text format     Abstract available


  10. FROLKIS AD, Vallerand IA, Patten SB, Kaplan GG, et al
    Depression in inflammatory bowel disease: risk factor, prodrome or extraintestinal manifestation? Reply from authors.
    Gut. 2019 Mar 20. pii: gutjnl-2019-318650. doi: 10.1136/gutjnl-2019-318650.
    PubMed     Text format    


  11. ZUO T, Lu XJ, Zhang Y, Cheung CP, et al
    Gut mucosal virome alterations in ulcerative colitis.
    Gut. 2019 Mar 6. pii: gutjnl-2018-318131. doi: 10.1136/gutjnl-2018-318131.
    PubMed     Text format     Abstract available


    February 2019
  12. MOULTON CD, Norton C, Powell N, Mohamedali Z, et al
    Depression in inflammatory bowel disease: risk factor, prodrome or extraintestinal manifestation?
    Gut. 2019 Feb 26. pii: gutjnl-2019-318444. doi: 10.1136/gutjnl-2019-318444.
    PubMed     Text format    


  13. BLACKWELL J, Saxena S, Pollok RC
    Changing trends in coding for depression among the UK inflammatory bowel disease population.
    Gut. 2019 Feb 13. pii: gutjnl-2019-318296. doi: 10.1136/gutjnl-2019-318296.
    PubMed     Text format    


  14. HARPAZ N, Ballentine S, Colombel JF, E Sands B, et al
    Microscopic heterogeneity in ulcerative colitis: implications for microscopic measurement of disease activity.
    Gut. 2019 Feb 5. pii: gutjnl-2018-318137. doi: 10.1136/gutjnl-2018-318137.
    PubMed     Text format    


  15. SAHNAN K, Tozer PJ, Adegbola SO, Lee MJ, et al
    Developing a core outcome set for fistulising perianal Crohn's disease.
    Gut. 2019;68:226-238.
    PubMed     Text format     Abstract available


  16. LEVINE A, Kori M, Kierkus J, Sigall Boneh R, et al
    Azithromycin and metronidazole versus metronidazole-based therapy for the induction of remission in mild to moderate paediatric Crohn's disease : a randomised controlled trial.
    Gut. 2019;68:239-247.
    PubMed     Text format     Abstract available


    January 2019
  17. VIGOD SN, Kurdyak P, Brown HK, Nguyen GC, et al
    Inflammatory bowel disease and new-onset psychiatric disorders in pregnancy and post partum: a population-based cohort study.
    Gut. 2019 Jan 9. pii: gutjnl-2018-317610. doi: 10.1136/gutjnl-2018-317610.
    PubMed     Text format     Abstract available


  18. ROGLER G
    Mechanism of action of vedolizumab: do we really understand it?
    Gut. 2019;68:4-5.
    PubMed     Text format    


  19. HUTFLESS S, Wenning GK
    Which way does the axis tip? IBD increases the risk of Parkinson's disease.
    Gut. 2019;68:3.
    PubMed     Text format    


  20. GOUYNOU C, Pouillon L, Rousseau H, Zallot C, et al
    Early changes in the pharmacokinetic profile of vedolizumab-treated patients with IBD may predict response after dose optimisation.
    Gut. 2019;68:178-179.
    PubMed     Text format    


  21. DANESE S, Vermeire S, Hellstern P, Panaccione R, et al
    Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II).
    Gut. 2019;68:40-48.
    PubMed     Text format     Abstract available


    December 2018
  22. IACUCCI M, Furfaro F, Matsumoto T, Uraoka T, et al
    Advanced endoscopic techniques in the assessment of inflammatory bowel disease: new technology, new era.
    Gut. 2018 Dec 22. pii: gutjnl-2017-315235. doi: 10.1136/gutjnl-2017-315235.
    PubMed     Text format     Abstract available


  23. BLACKWELL J, Saxena S, Pollok RC
    Role of thiopurines as disease-modifying agents in Crohn's disease.
    Gut. 2018;67:2229-2230.
    PubMed     Text format    


    November 2018
  24. UNGARO RC, Limketkai BN, Jensen CB, Allin KH, et al
    Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts.
    Gut. 2018 Nov 12. pii: gutjnl-2018-317021. doi: 10.1136/gutjnl-2018-317021.
    PubMed     Text format     Abstract available


    October 2018
  25. FROLKIS AD, Vallerand IA, Shaheen AA, Lowerison MW, et al
    Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression.
    Gut. 2018 Oct 18. pii: gutjnl-2018-317182. doi: 10.1136/gutjnl-2018-317182.
    PubMed     Text format     Abstract available


  26. HAMMOUDI N, Gardair C, Tran-Minh ML, Allez M, et al
    Rare cause of rectal stenosis in a patient with long-term use of Infliximab and Mercaptopurine for ulcerative colitis.
    Gut. 2018 Oct 9. pii: gutjnl-2018-317069. doi: 10.1136/gutjnl-2018-317069.
    PubMed     Text format     Abstract available


  27. XU P, Becker H, Elizalde M, Masclee A, et al
    Intestinal organoid culture model is a valuable system to study epithelial barrier function in IBD.
    Gut. 2018;67:1905-1906.
    PubMed     Text format    


  28. SANDBORN WJ, Lee SD, Tarabar D, Louis E, et al
    Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study.
    Gut. 2018;67:1824-1835.
    PubMed     Text format     Abstract available


  29. GERNER RR, Klepsch V, Macheiner S, Arnhard K, et al
    NAD metabolism fuels human and mouse intestinal inflammation.
    Gut. 2018;67:1813-1823.
    PubMed     Text format     Abstract available


    September 2018
  30. VAZQUEZ-BAEZA Y, Gonzalez A, Xu ZZ, Washburne A, et al
    Guiding longitudinal sampling in IBD cohorts.
    Gut. 2018;67:1743-1745.
    PubMed     Text format    


  31. LEVINE A, Sigall Boneh R, Wine E
    Evolving role of diet in the pathogenesis and treatment of inflammatory bowel diseases.
    Gut. 2018;67:1726-1738.
    PubMed     Text format     Abstract available


    August 2018
  32. TAN LZ, Reilly CR, Steward-Harrison LC, Balouch F, et al
    Oral vancomycin induces clinical and mucosal remission of colitis in children with primary sclerosing cholangitis-ulcerative colitis.
    Gut. 2018 Aug 21. pii: gutjnl-2018-316599. doi: 10.1136/gutjnl-2018-316599.
    PubMed     Text format    


  33. JAIRATH V, Peyrin-Biroulet L, Zou G, Mosli M, et al
    Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial.
    Gut. 2018 Aug 3. pii: gutjnl-2018-316702. doi: 10.1136/gutjnl-2018-316702.
    PubMed     Text format     Abstract available


  34. CONCEICAO-NETO N, Deboutte W, Dierckx T, Machiels K, et al
    Low eukaryotic viral richness is associated with faecal microbiota transplantation success in patients with UC.
    Gut. 2018;67:1558-1559.
    PubMed     Text format    


    July 2018
  35. POTTER MDE, Walker MM, Keely S, Talley NJ, et al
    What's in a name? 'Non-coeliac gluten or wheat sensitivity': controversies and mechanisms related to wheat and gluten causing gastrointestinal symptoms or disease.
    Gut. 2018 Jul 30. pii: gutjnl-2018-316360. doi: 10.1136/gutjnl-2018-316360.
    PubMed     Text format    


  36. MAO R, Chen Y, Xie X, Chen M, et al
    Gastrointestinal ultrasound in inflammatory bowel disease: experience from the Chinese IBD Elite Union.
    Gut. 2018 Jul 27. pii: gutjnl-2018-317070. doi: 10.1136/gutjnl-2018-317070.
    PubMed     Text format    


  37. WEIMERS P, Halfvarson J, Sachs MC, Ludvigsson JF, et al
    Association between inflammatory bowel disease and Parkinson's disease: seek and you shall find?
    Gut. 2018 Jul 18. pii: gutjnl-2018-316937. doi: 10.1136/gutjnl-2018-316937.
    PubMed     Text format    


  38. KIRCHGESNER J, Beaugerie L, Carrat F, Andersen NN, et al
    Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study.
    Gut. 2018;67:1261-1268.
    PubMed     Text format     Abstract available


    June 2018
  39. KOTZE PG, Shen B, Lightner A, Yamamoto T, et al
    Modern management of perianal fistulas in Crohn's disease: future directions.
    Gut. 2018;67:1181-1194.
    PubMed     Text format     Abstract available


  40. BISSCHOPS R, Bessissow T, Joseph JA, Baert F, et al
    Chromoendoscopy versus narrow band imaging in UC: a prospective randomised controlled trial.
    Gut. 2018;67:1087-1094.
    PubMed     Text format     Abstract available


  41. ZHOU G, Yu L, Fang L, Yang W, et al
    CD177(+) neutrophils as functionally activated neutrophils negatively regulate IBD.
    Gut. 2018;67:1052-1063.
    PubMed     Text format     Abstract available


    May 2018
  42. VILLUMSEN M, Aznar S, Pakkenberg B, Jess T, et al
    Inflammatory bowel disease increases the risk of Parkinson's disease: a Danish nationwide cohort study 1977-2014.
    Gut. 2018 May 21. pii: gutjnl-2017-315666. doi: 10.1136/gutjnl-2017-315666.
    PubMed     Text format     Abstract available


  43. ZEISSIG S, Rosati E, Dowds CM, Aden K, et al
    Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.
    Gut. 2018 May 5. pii: gutjnl-2018-316023. doi: 10.1136/gutjnl-2018-316023.
    PubMed     Text format     Abstract available


  44. TEN HOVE JR, Shah SC, Shaffer SR, Bernstein CN, et al
    Consecutive negative findings on colonoscopy during surveillance predict a low risk of advanced neoplasia in patients with inflammatory bowel disease with long-standing colitis: results of a 15-year multicentre, multinational cohort study.
    Gut. 2018 May 2. pii: gutjnl-2017-315440. doi: 10.1136/gutjnl-2017-315440.
    PubMed     Text format     Abstract available


  45. VAN STAPPEN T, Vande Casteele N, Van Assche G, Ferrante M, et al
    Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial.
    Gut. 2018;67:818-826.
    PubMed     Text format     Abstract available


    April 2018
  46. ERIKSSON C, Rundquist S, Cao Y, Montgomery S, et al
    Impact of thiopurines on the natural history and surgical outcome of ulcerative colitis: a cohort study.
    Gut. 2018 Apr 4. pii: gutjnl-2017-315521. doi: 10.1136/gutjnl-2017-315521.
    PubMed     Text format     Abstract available


  47. MOUSSATA D, Allez M, Cazals-Hatem D, Treton X, et al
    Are random biopsies still useful for the detection of neoplasia in patients with IBD undergoing surveillance colonoscopy with chromoendoscopy?
    Gut. 2018;67:616-624.
    PubMed     Text format     Abstract available


    March 2018
  48. OKUGAWA Y, Toiyama Y, Kusunoki M, Goel A, et al
    Re: Cumulative burden of inflammation predicts colorectal neoplasia risk in ulcerative colitis: a large single-centre study.
    Gut. 2018 Mar 13. pii: gutjnl-2018-316205. doi: 10.1136/gutjnl-2018-316205.
    PubMed     Text format    


    February 2018
  49. BRYANT RV, Friedman A, Wright EK, Taylor K, et al
    Gastrointestinal ultrasound in inflammatory bowel disease: an underused resource with potential paradigm-changing application.
    Gut. 2018 Feb 3. pii: gutjnl-2017-315655. doi: 10.1136/gutjnl-2017-315655.
    PubMed     Text format     Abstract available


  50. LAHARIE D, Bourreille A, Branche J, Allez M, et al
    Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab.
    Gut. 2018;67:237-243.
    PubMed     Text format     Abstract available


  51. SIEGEL CA, Whitman CB, Spiegel BMR, Feagan B, et al
    Development of an index to define overall disease severity in IBD.
    Gut. 2018;67:244-254.
    PubMed     Text format     Abstract available


    January 2018
  52. ORTQVIST AK, Lundholm C, Halfvarson J, Ludvigsson JF, et al
    Fetal and early life antibiotics exposure and very early onset inflammatory bowel disease: a population-based study.
    Gut. 2018 Jan 10. pii: gutjnl-2017-314352. doi: 10.1136/gutjnl-2017-314352.
    PubMed     Text format     Abstract available


  53. BOUHNIK Y, Carbonnel F, Laharie D, Stefanescu C, et al
    Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study.
    Gut. 2018;67:53-60.
    PubMed     Text format     Abstract available


  54. ARIJS I, De Hertogh G, Lemmens B, Van Lommel L, et al
    Effect of vedolizumab (anti-alpha4beta7-integrin) therapy on histological healing and mucosal gene expression in patients with UC.
    Gut. 2018;67:43-52.
    PubMed     Text format     Abstract available


  55. WEISER M, Simon JM, Kochar B, Tovar A, et al
    Molecular classification of Crohn's disease reveals two clinically relevant subtypes.
    Gut. 2018;67:36-42.
    PubMed     Text format     Abstract available


  56. CARBALLAL S, Maisterra S, Lopez-Serrano A, Gimeno-Garcia AZ, et al
    Real-life chromoendoscopy for neoplasia detection and characterisation in long-standing IBD.
    Gut. 2018;67:70-78.
    PubMed     Text format     Abstract available


  57. BOUHNIK Y, Mary JY
    Adalimumab in Crohn's disease and symptomatic small bowel strictures.
    Gut. 2018;67:199.
    PubMed     Text format    


  58. SONAMBEKAR AA, Desai DC, Joshi A, Dhoble P, et al
    Adalimumab in Crohn's strictures--the CREOLE study.
    Gut. 2018;67:198.
    PubMed     Text format    


    December 2017
  59. DANESE S, Fiorino G, Peyrin-Biroulet L
    Early intervention in Crohn's disease: towards disease modification trials.
    Gut. 2017;66:2179-2187.
    PubMed     Text format     Abstract available


  60. COLOMBEL JF, Keir ME, Scherl A, Zhao R, et al
    Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC.
    Gut. 2017;66:2063-2068.
    PubMed     Text format     Abstract available


    November 2017
  61. CHOI CR, Al Bakir I, Ding NJ, Lee GH, et al
    Cumulative burden of inflammation predicts colorectal neoplasia risk in ulcerative colitis: a large single-centre study.
    Gut. 2017 Nov 17. pii: gutjnl-2017-314190. doi: 10.1136/gutjnl-2017-314190.
    PubMed     Text format     Abstract available


  62. PALMELA C, Chevarin C, Xu Z, Torres J, et al
    Adherent-invasive Escherichia coli in inflammatory bowel disease.
    Gut. 2017 Nov 15. pii: gutjnl-2017-314903. doi: 10.1136/gutjnl-2017-314903.
    PubMed     Text format     Abstract available


  63. KIM HS, Cheon JH, Jung ES, Park J, et al
    A coding variant in FTO confers susceptibility to thiopurine-induced leukopenia in East Asian patients with IBD.
    Gut. 2017;66:1926-1935.
    PubMed     Text format     Abstract available


  64. ZUNDLER S, Schillinger D, Fischer A, Atreya R, et al
    Blockade of alphaEbeta7 integrin suppresses accumulation of CD8+ and Th9 lymphocytes from patients with IBD in the inflamed gut in vivo.
    Gut. 2017;66:1936-1948.
    PubMed     Text format     Abstract available


  65. ALLEZ M, Skolnick BE, Wisniewska-Jarosinska M, Petryka R, et al
    Anti-NKG2D monoclonal antibody (NNC0142-0002) in active Crohn's disease: a randomised controlled trial.
    Gut. 2017;66:1918-1925.
    PubMed     Text format     Abstract available


  66. HOCHART A, Gower-Rousseau C, Sarter H, Fumery M, et al
    Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study.
    Gut. 2017;66:1912-1917.
    PubMed     Text format     Abstract available


  67. HOVING JC, Cutler AJ, Leeto M, Horsnell WGC, et al
    Interleukin 13-mediated colitis in the absence of IL-4Ralpha signalling.
    Gut. 2017;66:2037-2039.
    PubMed     Text format    


    October 2017
  68. NORGARD BM, Magnussen B, Larsen MD, Friedman S, et al
    Reassuring results on birth outcomes in children fathered by men treated with azathioprine/6-mercaptopurine within 3 months before conception: a nationwide cohort study.
    Gut. 2017;66:1761-1766.
    PubMed     Text format     Abstract available


  69. JULSGAARD M, Kjeldsen J, Baumgart DC
    Vedolizumab safety in pregnancy and newborn outcomes.
    Gut. 2017;66:1866-1867.
    PubMed     Text format    


  70. SOMMER F, Ruhlemann MC, Bang C, Hoppner M, et al
    Microbiomarkers in inflammatory bowel diseases: caveats come with caviar.
    Gut. 2017;66:1734-1738.
    PubMed     Text format    


    September 2017
  71. BERTIN S, Aoki-Nonaka Y, Lee J, de Jong PR, et al
    The TRPA1 ion channel is expressed in CD4+ T cells and restrains T-cell-mediated colitis through inhibition of TRPV1.
    Gut. 2017;66:1584-1596.
    PubMed     Text format     Abstract available


  72. GURVITS GE
    When radiology meets gastroenterology: an unusual impact.
    Gut. 2017;66:1676.
    PubMed     Text format    


    August 2017
  73. PARIAN A, Limketkai B, Koh J, Brant SR, et al
    Appendectomy does not decrease the risk of future colectomy in UC: results from a large cohort and meta-analysis.
    Gut. 2017;66:1390-1397.
    PubMed     Text format     Abstract available


  74. NYBOE ANDERSEN N, Gortz S, Frisch M, Jess T, et al
    Reduced risk of UC in families affected by appendicitis: a Danish national cohort study.
    Gut. 2017;66:1398-1402.
    PubMed     Text format     Abstract available


  75. O'BRIEN CL, Bringer MA, Holt KE, Gordon DM, et al
    Comparative genomics of Crohn's disease-associated adherent-invasive Escherichia coli.
    Gut. 2017;66:1382-1389.
    PubMed     Text format     Abstract available


    July 2017
  76. SPILLER RC, Sloan TJ
    Do diverticula provide a unique niche for microbiota which can lead to activation of the innate immune system?
    Gut. 2017;66:1175-1176.
    PubMed     Text format    


    June 2017
  77. PANES J, Sandborn WJ, Schreiber S, Sands BE, et al
    Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials.
    Gut. 2017;66:1049-1059.
    PubMed     Text format     Abstract available


  78. SCHWERD T, Pandey S, Yang HT, Bagola K, et al
    Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann-Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn's disease.
    Gut. 2017;66:1060-1073.
    PubMed     Text format     Abstract available


  79. SOKOL H, Leducq V, Aschard H, Pham HP, et al
    Fungal microbiota dysbiosis in IBD.
    Gut. 2017;66:1039-1048.
    PubMed     Text format     Abstract available


    May 2017
  80. PARANG B, Kaz AM, Barrett CW, Short SP, et al
    BVES regulates c-Myc stability via PP2A and suppresses colitis-induced tumourigenesis.
    Gut. 2017;66:852-862.
    PubMed     Text format     Abstract available


  81. PASCAL V, Pozuelo M, Borruel N, Casellas F, et al
    A microbial signature for Crohn's disease.
    Gut. 2017;66:813-822.
    PubMed     Text format     Abstract available


  82. LEE T, Clavel T, Smirnov K, Schmidt A, et al
    Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD.
    Gut. 2017;66:863-871.
    PubMed     Text format     Abstract available


  83. SCHEIBE K, Backert I, Wirtz S, Hueber A, et al
    IL-36R signalling activates intestinal epithelial cells and fibroblasts and promotes mucosal healing in vivo.
    Gut. 2017;66:823-838.
    PubMed     Text format     Abstract available


    April 2017
  84. LORD AR, Simms LA, Hanigan K, Sullivan R, et al
    Protective effects of Helicobacter pylori for IBD are related to the cagA-positive strain.
    Gut. 2017 Apr 13. pii: gutjnl-2017-313805. doi: 10.1136/gutjnl-2017-313805.
    PubMed     Text format    


  85. LIN W, Ma C, Su F, Jiang Y, et al
    Raf kinase inhibitor protein mediates intestinal epithelial cell apoptosis and promotes IBDs in humans and mice.
    Gut. 2017;66:597-610.
    PubMed     Text format     Abstract available


    March 2017
  86. FRIEDMAN S, Larsen PV, Fedder J, Norgard BM, et al
    The reduced chance of a live birth in women with IBD receiving assisted reproduction is due to a failure to achieve a clinical pregnancy.
    Gut. 2017;66:556-558.
    PubMed     Text format    


    February 2017
  87. NOBEN M, Verstockt B, de Bruyn M, Hendriks N, et al
    Epithelial organoid cultures from patients with ulcerative colitis and Crohn's disease: a truly long-term model to study the molecular basis for inflammatory bowel disease?
    Gut. 2017 Feb 3. pii: gutjnl-2016-313667. doi: 10.1136/gutjnl-2016-313667.
    PubMed     Text format    


  88. SUBRAMANIAN S, Ekbom A, Rhodes JM
    Recent advances in clinical practice: a systematic review of isolated colonic Crohn's disease: the third IBD?
    Gut. 2017;66:362-381.
    PubMed     Text format     Abstract available


  89. CASTANO-RODRIGUEZ N, Kaakoush NO, Lee WS, Mitchell HM, et al
    Dual role of Helicobacter and Campylobacter species in IBD: a systematic review and meta-analysis.
    Gut. 2017;66:235-249.
    PubMed     Text format     Abstract available


  90. QURAISHI MN, Sergeant M, Kay G, Iqbal T, et al
    The gut-adherent microbiota of PSC-IBD is distinct to that of IBD.
    Gut. 2017;66:386-388.
    PubMed     Text format    


    January 2017
  91. MOSLI MH, Feagan BG, Zou G, Sandborn WJ, et al
    Development and validation of a histological index for UC.
    Gut. 2017;66:50-58.
    PubMed     Text format     Abstract available


  92. MARCHAL-BRESSENOT A, Salleron J, Boulagnon-Rombi C, Bastien C, et al
    Development and validation of the Nancy histological index for UC.
    Gut. 2017;66:43-49.
    PubMed     Text format     Abstract available


  93. MACHIELS K, Sabino J, Vandermosten L, Joossens M, et al
    Specific members of the predominant gut microbiota predict pouchitis following colectomy and IPAA in UC.
    Gut. 2017;66:79-88.
    PubMed     Text format     Abstract available


  94. ATREYA I, Neurath MF
    Microbiota: relevant player in thiopurine metabolisation?
    Gut. 2017;66:1-3.
    PubMed     Text format    


  95. DONG R, Zheng S, Chen G
    The appropriate dose and cost of iron replacement therapy in patients with IBD.
    Gut. 2017;66:196-197.
    PubMed     Text format    


  96. GUINET-CHARPENTIER C, Lepage P, Morali A, Chamaillard M, et al
    Effects of enteral polymeric diet on gut microbiota in children with Crohn's disease.
    Gut. 2017;66:194-195.
    PubMed     Text format    


    November 2016
  97. OLIVERA P, Danese S, Peyrin-Biroulet L
    Next generation of small molecules in inflammatory bowel disease.
    Gut. 2016 Nov 17. pii: gutjnl-2016-312912. doi: 10.1136/gutjnl-2016-312912.
    PubMed     Text format    


  98. TEICH N, Bokemeyer B, Mohl W, Walldorf J, et al
    Blood group B is associated with azathioprine-induced acute pancreatitis in patients with IBD.
    Gut. 2016 Nov 14. pii: gutjnl-2016-313138. doi: 10.1136/gutjnl-2016-313138.
    PubMed     Text format    


  99. DOTTI I, Mora-Buch R, Ferrer-Picon E, Planell N, et al
    Alterations in the epithelial stem cell compartment could contribute to permanent changes in the mucosa of patients with ulcerative colitis.
    Gut. 2016 Nov 1. pii: gutjnl-2016-312609. doi: 10.1136/gutjnl-2016-312609.
    PubMed     Text format     Abstract available


    October 2016
  100. IMHANN F, Vich Vila A, Bonder MJ, Fu J, et al
    Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease.
    Gut. 2016 Oct 8. pii: gutjnl-2016-312135. doi: 10.1136/gutjnl-2016-312135.
    PubMed     Text format     Abstract available


    September 2016
  101. HASLER R, Sheibani-Tezerji R, Sinha A, Barann M, et al
    Uncoupling of mucosal gene regulation, mRNA splicing and adherent microbiota signatures in inflammatory bowel disease.
    Gut. 2016 Sep 30. pii: gutjnl-2016-311651. doi: 10.1136/gutjnl-2016-311651.
    PubMed     Text format     Abstract available


    July 2016
  102. JENDREK ST, Gotthardt D, Nitzsche T, Widmann L, et al
    Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis.
    Gut. 2016 Jul 12. pii: gutjnl-2016-311739. doi: 10.1136/gutjnl-2016-311739.
    PubMed     Text format     Abstract available


    May 2016
  103. SABINO J, Vieira-Silva S, Machiels K, Joossens M, et al
    Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD.
    Gut. 2016 May 20. pii: gutjnl-2015-311004. doi: 10.1136/gutjnl-2015-311004.
    PubMed     Text format     Abstract available


    June 2015
  104. HART PA, Levy MJ, Smyrk TC, Takahashi N, et al
    Clinical profiles and outcomes in idiopathic duct-centric chronic pancreatitis (type 2 autoimmune pancreatitis): the Mayo Clinic experience.
    Gut. 2015 Jun 17. pii: gutjnl-2015-309275. doi: 10.1136/gutjnl-2015-309275.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: